- Claude Fable 5 is a Mythos-class model that we’ve made safe for general use.
- Fable 5’s capabilities exceed those of any model we’ve ever made generally available.
- For a small group of cyberdefenders and infrastructure providers, we’re also launching Claude Mythos 5.
- Mythos 5 will initially be deployed through, in collaboration with the US government.
- Fable 5 and Mythos 5 are being offered at $10 per million input tokens and $50 per million output tokens—less than half the price of Claude Mythos Preview.
- Fable 5 shows strong performance on complex analytical tasks.
- On Finance Benchmark for senior-level reasoning, Fable 5 has the highest score of any model.
- Using Mythos 5, our internal protein design experts accelerated aspects of the drug design process by around ten times.
- Mythos 5 is our first model to consistently produce novel, compelling scientific hypotheses.
- Mythos 5 conducted novel genomics research in over a week of largely autonomous work.
- Customers with early access ran their own tests on Fable 5.
- Claude Fable 5 is a real step forward for the developers GitHub serves.
- Our early data shows that more than 95% of Fable sessions involve no fallback at all.
- In April we began, releasing the first Mythos-class model (Claude Mythos Preview).
- Today’s joint launch is another step towards our goal of bringing advanced AI capabilities to as many users as possible.
Claude Fable 5 and Claude Mythos 5 were launched today, representing major advancements in AI for users and cyberdefenders.12345678910111213
Fable 5 is a Mythos-class model that excels in complex analytical tasks, achieving the highest score in senior-level reasoning on the Finance Benchmark, reflecting its superior capabilities.14
Furthermore, the pricing model is favorable, with Fable 5 and Mythos 5 offered at $10 per million input tokens and $50 per million output tokens, significantly undercutting the previous Claude Mythos Preview prices.
Mythos 5, designed for specialized users, showcases groundbreaking performance, accelerating drug design process by approximately tenfold through novel genomics research with largely autonomous capabilities. This model produces unique scientific hypotheses, which elevate the standards of research and analytics in the sector.
Early adopters have reported that over 95% of sessions with Fable 5 involved no fallback, attesting to its reliability. The simultaneous launch of both models signifies a strategic move to extend advanced AI capabilities to a broader audience, fulfilling the developers' commitment to innovate within this space.15
“Today’s joint launch is another step towards our goal of bringing advanced AI capabilities to as many users as possible,” as stated by the company’s spokesperson.
The collaboration on Mythos 5 with the US government also highlights the initiative's focus on cybersecurity and infrastructure resilience, marking a significant development in AI deployment.
“Claude Fable 5 and Claude Mythos 5 have been launched, promising to enhance AI capabilities for users and infrastructure providers. Notably, Mythos 5 accelerates drug design by ten times and consistently generates novel scientific hypotheses.”
